CORCEPT THERAPEUTICS INC 4

Sean Maduck exercised 1,031 stock options and sold 1,031 Corcept Therapeutics (CORT) common shares on August 10, 2026 under a 10b5-1 plan for roughly $118,000 in proceeds.

On August 10, 2026, Sean Maduck, President, Corcept Endocrinology at Corcept Therapeutics Inc., exercised 1,031 stock options at an exercise price of $8.27 per share and immediately sold the same 1,031 common shares at a weighted average price of $114.5182 per share pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025, generating an estimated transaction value of about $118,000. Following these transactions, he reported direct ownership of 9,755 common shares (including 1,502 unvested restricted shares) and indirect ownership of multiple additional blocks of common stock—5,147 shares held by the Sean and Molly Maduck Living Trust, 20,570 shares held by MMM 2025, LLC, 40,000 shares held by SNM 2025 Grantor Retained Annuity Trust, 34,000 shares held by SNM 2026 Grantor Retained Annuity Trust, and 10,000 shares held by Duckhill Capital, LLC—bringing his total reported beneficial interest to approximately 119,472 shares, with an estimated post-transaction value of roughly $13.7 million based on the reported sale price.

Filing Facts

CIK

1088856

Ticker

CORT

Form

4

Source Type

fda

Accession

0001193125-26-346951

Alert Tier

5